[go: up one dir, main page]

PL2510942T3 - Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca - Google Patents

Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca

Info

Publication number
PL2510942T3
PL2510942T3 PL12156696T PL12156696T PL2510942T3 PL 2510942 T3 PL2510942 T3 PL 2510942T3 PL 12156696 T PL12156696 T PL 12156696T PL 12156696 T PL12156696 T PL 12156696T PL 2510942 T3 PL2510942 T3 PL 2510942T3
Authority
PL
Poland
Prior art keywords
heart failure
natriuretic peptide
treating heart
treating
natriuretic
Prior art date
Application number
PL12156696T
Other languages
English (en)
Inventor
Veselin Mitrovic
Hartmut Lüss
Wolf-Georg Forssmann
Markus Meyer
Klaus-Dieter Döhler
Original Assignee
Cardiorentis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiorentis Ag filed Critical Cardiorentis Ag
Publication of PL2510942T3 publication Critical patent/PL2510942T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL12156696T 2005-04-07 2006-04-07 Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca PL2510942T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66978605P 2005-04-07 2005-04-07
US66975105P 2005-04-08 2005-04-08
US73258505P 2005-11-01 2005-11-01
EP06749753A EP1865976B1 (en) 2005-04-07 2006-04-07 Use of natriuretic peptide for treating heart failure
EP12156696.2A EP2510942B1 (en) 2005-04-07 2006-04-07 Use of natriuretic peptide for treating heart failure

Publications (1)

Publication Number Publication Date
PL2510942T3 true PL2510942T3 (pl) 2016-02-29

Family

ID=37087353

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12156696T PL2510942T3 (pl) 2005-04-07 2006-04-07 Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
PL06749753T PL1865976T3 (pl) 2005-04-07 2006-04-07 Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06749753T PL1865976T3 (pl) 2005-04-07 2006-04-07 Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca

Country Status (10)

Country Link
US (5) US7732406B2 (pl)
EP (2) EP2510942B1 (pl)
CY (1) CY1113183T1 (pl)
DK (2) DK1865976T3 (pl)
ES (2) ES2392892T3 (pl)
HU (1) HUE026231T2 (pl)
PL (2) PL2510942T3 (pl)
PT (2) PT2510942E (pl)
SI (1) SI2510942T1 (pl)
WO (1) WO2006110743A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
ES2392892T3 (es) 2005-04-07 2012-12-14 Cardiopep Pharma Gmbh Uso de un péptido natriurético para tratar insuficiencia cardiaca
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
KR101581476B1 (ko) 2007-07-20 2015-12-30 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 나트륨이뇨성 폴리펩티드
ES2575397T3 (es) * 2007-09-11 2016-06-28 Cardiopep Pharma Gmbh Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
EP2078530A1 (en) * 2008-01-08 2009-07-15 Pharis Biotec GmbH Use of natriuretic peptides for treating angioedema syndromes
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2011113825A1 (en) * 2010-03-15 2011-09-22 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US20120277155A1 (en) * 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
AU2012287226A1 (en) * 2011-07-27 2014-02-20 Capricor Therapeutics, Inc. Natriuretic peptide compositions and methods of preparation
EP2751136B1 (en) 2011-08-30 2017-10-18 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2948165A2 (en) * 2013-01-25 2015-12-02 Cardiorentis Ltd. A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS WITH ALKALINE PHOSPHATASES
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
BR112019020506A2 (pt) 2017-03-31 2020-08-04 Alexion Pharmaceuticals, Inc. métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes
CN109838289B (zh) * 2017-11-27 2022-03-15 罗伯特·博世有限公司 尿素水溶液喷射系统的回抽过程监测系统和方法
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
KR20220111693A (ko) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
WO2021183928A1 (en) * 2020-03-13 2021-09-16 Mayo Foundation For Medical Education And Research Assessing and treating acute decompensated heart failure
WO2022029499A1 (en) * 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites
KR20230145120A (ko) 2021-02-12 2023-10-17 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
JP2819467B2 (ja) 1987-03-02 1998-10-30 ファーマ・ビッセンドルフ・ペプタイド・ゲーエムベーハー 新規なカルジオジラチン断片およびその製造方法
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
JPH10500969A (ja) 1994-06-02 1998-01-27 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング カルジオジラチンフラグメントの調製方法、高度に精製されたカルジオジラチンフラグメント及びそれらの調製のための中間生成物類
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
WO1998045329A1 (en) 1997-04-04 1998-10-15 Novo Nordisk A/S Natriuretic peptide derivatives
DE19951471A1 (de) * 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6831084B1 (en) 1999-11-12 2004-12-14 Wyeth Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
CA2425712C (en) 2000-10-04 2017-06-06 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
AU2003214210A1 (en) 2002-03-18 2003-10-08 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US7396829B2 (en) 2005-02-24 2008-07-08 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
ES2392892T3 (es) 2005-04-07 2012-12-14 Cardiopep Pharma Gmbh Uso de un péptido natriurético para tratar insuficiencia cardiaca
US20100168011A1 (en) 2006-12-12 2010-07-01 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations and Methods for Making the Same
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
CA2699169A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
ES2575397T3 (es) 2007-09-11 2016-06-28 Cardiopep Pharma Gmbh Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
EP2234603A1 (en) 2007-12-19 2010-10-06 EKR Therapeutics, Inc. Room temperature stable, lyophilized natriuretic peptide formulations
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US8642550B2 (en) 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
WO2010065293A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
US20110065676A1 (en) 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists
US20110014180A1 (en) 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
KR101768661B1 (ko) 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 신규한 ｎｐｒ－ｂ 길항제
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
WO2011113825A1 (en) 2010-03-15 2011-09-22 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
AU2011291586A1 (en) 2010-08-20 2013-03-07 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
WO2006110743A1 (en) 2006-10-19
US7732406B2 (en) 2010-06-08
EP2510942A1 (en) 2012-10-17
ES2554713T3 (es) 2015-12-22
US20150224174A1 (en) 2015-08-13
SI2510942T1 (sl) 2016-01-29
US20140287999A1 (en) 2014-09-25
US8710006B2 (en) 2014-04-29
EP1865976A4 (en) 2010-09-01
HUE026231T2 (en) 2016-06-28
EP1865976B1 (en) 2012-05-23
DK2510942T3 (en) 2015-12-14
EP1865976A1 (en) 2007-12-19
US9358271B2 (en) 2016-06-07
US20160324931A1 (en) 2016-11-10
US20110257099A1 (en) 2011-10-20
EP2510942B1 (en) 2015-09-02
DK1865976T3 (da) 2012-07-23
ES2392892T3 (es) 2012-12-14
PL1865976T3 (pl) 2012-11-30
PT2510942E (pt) 2015-12-28
US9023794B2 (en) 2015-05-05
PT1865976E (pt) 2012-08-03
CY1113183T1 (el) 2016-04-13
US20060264376A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
SI2510942T1 (sl) Uporaba natriuretskega peptida za zdravljenje srčne odpovedi
GB2440809B (en) Improved heart valve prosthesis
IL248964A0 (en) Arterial supports for the treatment of arterial blockages in the body
IL187703A0 (en) Treatment of protein folding disorders
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
IL189420A0 (en) Method for the recombinant expression of a polypeptid
TWI340645B (en) Solution for tissue adhesion prevention
GB2429013C (en) Peptides for treatment and diagnosis of autoimmunedisease
PL1685834T3 (pl) Zastosowanie kwasu pinolenowego do leczenia otyłości
EP1729687A4 (en) HEART VALVE
EP2091480A4 (en) SYSTEM FOR THE TREATMENT OF HEART TISSUE
EP1946724A4 (en) PROSTHESIS OF HEART VALVE
EP1923078A4 (en) TISSUE REGENERATION SUBSTRATE
PL1945243T3 (pl) Zastosowanie kalcytoniny w leczeniu rzs
EP1871462A4 (en) DC TISSUE TREATMENT
GB0505975D0 (en) Novel use of peptide
GB0525540D0 (en) New treatment
SI1865976T1 (sl) Uporaba natriuretskega peptida za zdravljenje srčne odpovedi
GB0609121D0 (en) Peptide Therapy
GB0526120D0 (en) Therapeutic peptides
EP1859803A4 (en) MEANS OF PROMOTING THE FORMATION OF HARD FABRIC
GB0618060D0 (en) Treatment of polyamides
EP2166020A4 (en) PEPTIDE HAVING HYPOTENSIVE ACTIVITY
IL186812A0 (en) Dc tissue treatment
GB0515776D0 (en) Insulin stimulating peptide